Skip to content

In the BioHarmony Drug Report Database

Nimodipine

Nimotop, Nymalize (nimodipine) is a small molecule pharmaceutical. Nimodipine was first approved as Nimotop on 1988-12-28. It is used to treat subarachnoid hemorrhage in the USA. The pharmaceutical is active against mineralocorticoid receptor. In addition, it is known to target cystic fibrosis transmembrane conductance regulator, voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1D, voltage-dependent L-type calcium channel subunit alpha-1S, voltage-dependent L-type calcium channel subunit alpha-1C, and Ion transport protein. Nymalize's patents are valid until 2038-04-16 (FDA).
Trade Name Nimotop, Nymalize
Common Name Nimodipine
Indication subarachnoid hemorrhage
Drug Class Phenylpyridine vasodilators (nifedipine type)
Nimodipine
Get full access now